Aurobindo Pharma Ltd’s fundamental analysis reveals key financial metrics: Market Cap of ₹83,276.52 crore, PE Ratio of 26.25, Debt to Equity of 19.69, and Return on Equity of 7.5%. These indicators offer insights into the company’s financial health and market valuation.
Content:
- Aurobindo Pharma Limited Overview
- Aurobindo Pharma Financial Results
- Aurobindo Pharma Ltd Financial Analysis
- Aurobindo Pharma Limited Company Metrics
- Aurobindo Pharma Stock Performance
- Aurobindo Pharma Ltd Peer Comparison
- Aurobindo Pharma Shareholding Pattern
- Aurobindo Pharma History
- How To Invest In Aurobindo Pharma Ltd Share?
- Aurobindo Pharma Limited Fundamental Analysis – FAQs
Aurobindo Pharma Limited Overview
Aurobindo Pharma Ltd is an Indian pharmaceutical company engaged in manufacturing and marketing active pharmaceutical ingredients and generic pharmaceuticals. It operates in the healthcare sector, focusing on various therapeutic areas.
The company is listed on both the NSE and BSE. With a market capitalization of ₹83,276.52 crore, it’s currently 2.08% away from its 52-week high and 74.22% away from its 52-week low.
Aurobindo Pharma Financial Results
Aurobindo Pharma demonstrated strong financial performance from FY23 to FY24, with sales increasing from ₹24,855 crores to ₹29,002 crores and operating profit rising significantly, reflecting the company’s robust growth trajectory and improved operational efficiency.
1. Revenue Trend: Sales increased from ₹24,855 crores in FY23 to ₹29,002 crores in FY24, marking a significant upward trend.
2. Equity and Liabilities: Equity capital remains steady at ₹58.59 crores, while total liabilities grew from ₹39,890 crores in FY23 to ₹45,072 crores in FY24, reflecting expanded financial commitments.
3. Profitability: Operating profit surged from ₹3,719 crores in FY23 to ₹5,843 crores in FY24, with OPM improving from 15% to 20%, indicating enhanced efficiency.
4. Earnings per Share (EPS): EPS increased from ₹32.90 in FY23 to ₹54.16 in FY24, reflecting stronger earnings for shareholders.
5. Return on Net Worth (RoNW): With increased profitability, RoNW is expected to improve, indicating better returns for equity investors.
6. Financial Position: Total assets rose from ₹39,890 crores in FY23 to ₹45,072 crores in FY24, showcasing the company’s growing financial strength.
Aurobindo Pharma Ltd Financial Analysis
| FY 24 | FY 23 | FY 22 | |
| Sales | 29,002 | 24,855 | 23,455 |
| Expenses | 23,159 | 21,137 | 19,069 |
| Operating Profit | 5,843 | 3,719 | 4,387 |
| OPM % | 20 | 15 | 19 |
| Other Income | 366 | 291 | 192 |
| EBITDA | 6,400 | 4,009 | 4,707 |
| Interest | 290 | 140 | 49 |
| Depreciation | 1,522 | 1,245 | 1,127 |
| Profit Before Tax | 4,397 | 2,624 | 3,404 |
| Tax % | 28 | 26 | 21 |
| Net Profit | 3,169 | 1,928 | 2,647 |
| EPS | 54.16 | 32.9 | 45.19 |
| Dividend Payout % | 8.31 | 9.12 | 19.92 |
* Consolidated Figures in Rs. Crores
Aurobindo Pharma Limited Company Metrics
Aurobindo Pharma Ltd’s company metrics include a market capitalization of ₹83,276.52 crores, a book value per share of ₹509 per share, and a face value of ₹1. With a debt-to-equity ratio of 19.69, a return on equity of 7.5%, and a 0.11% dividend yield, these figures underscore the company’s financial position and investment profile.
Market Capitalization:
Market Capitalization represents the total market value of Aurobindo Pharma’s outstanding shares, amounting to ₹83,276.52 crore.
Book Value:
The book value per share of Aurobindo Pharma is ₹509 indicating the value of the company’s net assets divided by its outstanding shares.
Face Value:
The face value of Aurobindo Pharma’s shares is ₹1, which is the original cost of the shares as stated on the certificate.
Asset Turnover Ratio:
The asset turnover ratio of 0.81 measures how efficiently Aurobindo Pharma uses its assets to generate revenue.
Total Debt:
The total debt of ₹5,286.21 crore represents the sum of all short-term and long-term debt obligations of Aurobindo Pharma.
Return on Equity (ROE):
The ROE of 7.5% measures Aurobindo Pharma’s profitability in generating income from its equity investments.
EBITDA (Q):
The quarterly EBITDA of ₹1,673.66 crore represents Aurobindo Pharma’s earnings before interest, taxes, depreciation, and amortization.
Dividend Yield:
The dividend yield of 0.11% shows the annual dividend payment as a percentage of Aurobindo Pharma’s current share price, indicating the return on investment from dividends alone.
Aurobindo Pharma Stock Performance
Aurobindo Pharma Ltd has demonstrated a return on investment of 67.7% over one year, 24.3% over three years, and 19.3% over five years, reflecting significant short-term growth and moderate long-term performance.
| Period | Return on Investment (%) |
| 1 Year | 67.7 |
| 3 Years | 24.3 |
| 5 Years | 19.3 |
Example: If an investor had invested ₹1,000 in Aurobindo Pharma’s stock:
1 year ago, their investment would be worth ₹1,677.
3 years ago, their investment would have grown to ₹1,243.
5 years ago, their investment would be worth approximately ₹1,193.
Aurobindo Pharma Ltd Peer Comparison
Aurobindo Pharma Ltd, with a market cap of ₹88,389 crore and a P/E ratio of 25, has a 1-year return of 68%. In comparison, Sun Pharma (₹4,17,508 crore, P/E 40) has a 53% return, while Cipla (₹1,27,941 crore, P/E 29) has a return of 28%.
| Name | CMP Rs. | Mar Cap Rs.Cr. | P/E | ROE % | EPS 12M Rs. | 1Yr return % | ROCE % | Div Yld % |
| Sun Pharma.Inds. | 1,740 | 4,17,508 | 40 | 17 | 43 | 53 | 17 | 0.79 |
| Cipla | 1,584 | 1,27,941 | 29 | 17 | 53 | 28 | 23 | 0.82 |
| Zydus Lifesci. | 1,176 | 1,18,283 | 28 | 21 | 42 | 95 | 22.34 | 0.25 |
| Dr Reddy’s Labs | 6,948 | 1,15,920 | 21 | 21 | 334 | 18.26 | 26.53 | 0.58 |
| Lupin | 2,094 | 95,478 | 42 | 14 | 50 | 94 | 16 | 0.39 |
| Aurobindo Pharma | 1,509 | 88,389 | 25 | 12 | 60 | 68 | 14.1 | 0.31 |
| Mankind Pharma | 2,173 | 87,058 | 47 | 20 | 48 | 18 | 24.57 | – |
Aurobindo Pharma Shareholding Pattern
Aurobindo Pharma Ltd’s shareholding pattern for Jun-24 shows Promoters holding 51.8%, down slightly from 51.83% in Mar-24. FII holdings decreased from 18.01% to 16.73%. DII holdings rose from 23.28% to 24.77%, while Retail & others held steady around 6.69%.
| All values in % | Jun-24 | Mar-24 | Dec-23 |
| Promoters | 51.8 | 51.83 | 52 |
| FII | 16.73 | 18.01 | 20.72 |
| DII | 24.77 | 23.28 | 20.6 |
| Retail & others | 6.69 | 6.87 | 6.85 |
Aurobindo Pharma History
Aurobindo Pharma Limited, an India-based pharmaceutical company, specializes in manufacturing and marketing active pharmaceutical ingredients, branded and generic pharmaceuticals, and related services. Its diverse product portfolio spans seven therapeutic areas, including Central Nervous System, Antiretrovirals, and Cardiovascular.
The company is actively developing oncology and hormonal products, as well as topical and transdermal solutions in dermatology. It’s also working on innovative depot injections using microsphere and nano-suspension technology platforms, showcasing its commitment to research and development.
With a global presence in approximately 150 countries, Aurobindo Pharma has established itself as a significant player in the pharmaceutical industry. The company operates through various subsidiaries, including APL Healthcare Limited, Auronext Pharma Private Limited, and Auro Peptides Limited, enhancing its market reach and capabilities.
How To Invest In Aurobindo Pharma Ltd Share?
To invest in Aurobindo Pharma shares, open a demat account with Alice Blue. Research the company’s fundamentals and market trends before making investment decisions.
Determine your investment strategy, whether long-term holding or short-term trading. Consider seeking advice from a financial advisor for personalized guidance based on your financial goals.
When ready, place your order through the broker’s platform. Regularly monitor your investment, staying updated on company news and market conditions to make informed decisions.
Aurobindo Pharma Limited Fundamental Analysis – FAQs
Aurobindo Pharma Ltd’s fundamental analysis reveals a Market Cap of ₹83,276.52 crore, PE Ratio of 26.25, Debt to Equity of 19.69, and Return on Equity of 7.5%. These metrics provide insights into the company’s financial health, profitability, and market valuation.
Aurobindo Pharma’s market capitalization is ₹83,276.52 crore. This figure represents the total value of the company’s outstanding shares in the stock market, calculated by multiplying the current stock price by the number of outstanding shares.
Aurobindo Pharma Limited is an Indian pharmaceutical company specializing in manufacturing and marketing active pharmaceutical ingredients, generic drugs, and related services. It operates globally, focusing on various therapeutic areas including cardiovascular, antiretrovirals, and central nervous system medications.
Aurobindo Pharma was founded by P.V. Ramprasad Reddy and K. Nityananda Reddy. As a public company, it’s owned by shareholders, with the founding family maintaining significant ownership. The exact ownership structure may have changed since my last update.
The main shareholders of Aurobindo Pharma Ltd typically include the founding family (Reddys), institutional investors, and public shareholders. Specific ownership percentages may have changed. For the most current information, refer to the company’s latest shareholding pattern disclosure.
Aurobindo Pharma operates in the pharmaceutical industry. It specializes in manufacturing and marketing generic pharmaceuticals, active pharmaceutical ingredients (APIs), and related services. The company focuses on various therapeutic areas, contributing to the global healthcare and medicine sectors.
To invest in Aurobindo Pharma shares, open a demat account with Alice Blue. Research the company’s performance and industry trends. Decide on your investment strategy. Place your order through the broker’s platform. Regularly monitor your investment, staying informed about company news and market conditions. Consider seeking financial advice for personalized guidance.
Determining if Aurobindo Pharma is overvalued or undervalued requires an in-depth analysis of its financials, growth prospects, industry trends, and comparison with peers. Factors like PE ratio, market cap, and future earnings potential should be considered. Consult recent analyst reports for expert opinions.
